Evogene reported a significant reduction in operating expenses, reflecting the successful implementation of its strategic shift towards computational chemistry, while also generating income from divestitures.

• Operating expenses decreased to approximately $2.9 million, down from $6.6 million in Q3 2024, following a cost reduction plan.
• The sale of Lavie Bio's majority activities contributed approximately $7.9 million in income for the third quarter.
• Total operating loss improved to around $8.8 million, compared to a loss of $15.3 million in the same period last year.
• Cash and short-term deposits stand at approximately $16 million, bolstered by recent divestitures.
• Revenue for the first nine months of 2025 was approximately $3.5 million, reflecting lower AgPlenus revenue but increased seed sales from Casterra.